基因组检测使低中危黑人前列腺癌患者NCCN风险升级
该回顾性研究纳入63例依据NCCN指南符合主动监测条件的黑人前列腺癌患者,均在2016年4月至2020年7月间接受OncotypeDx基因组前列腺评分检测。基因组检测后NCCN风险分类整体显著高于初始分类(P=.003),40例风险不一致者中28例(70%)被上调风险。
要点
- 基因组检测后NCCN风险分类整体显著升高(P=.003)
- 40例风险不一致者中28例(70%)被重新归类为更高风险
- favourable intermediate risk患者中20例(64.5%)风险上调
核心结论
- 在低、中危黑人前列腺癌患者中纳入基因组检测使NCCN风险分类整体升高,提示基因组检测有助于细化该人群的风险分层并支持个体化治疗决策。
研究设计与样本
- 回顾性研究,纳入63例依据NCCN指南符合主动监测条件并接受OncotypeDx基因组前列腺评分检测的黑人前列腺癌患者,检测时间为2016年4月至2020年7月。
- 采用非参数统计方法比较基因组检测后风险上调与未上调患者的相关特征。
主要发现
- 中位年龄66岁,活检前中位PSA为7.3。
- 初始风险分类为:极低危7例(11.1%)、低危24例(38.1%)、 favourable intermediate risk 31例(49.2%)、 unfavorable intermediate risk 1例(1.6%)。
- 基因组检测后NCCN风险分类显著高于初始分类(P=.003,Wilcoxon符号秩检验)。
- 风险不一致患者中28例(28/40,70%)经基因组检测被重新归类为更高NCCN风险。
- 活检前PSA大于10与更高风险分类的关联无统计学意义(OR:2.16 [95%CI:0.64,7.59],P=.2); favourable intermediate risk患者中20例(64.5%)风险上调;最终18例接受确定性治疗。
临床怎么用
- 对符合主动监测条件的低、中危黑人前列腺癌患者,可考虑增加基因组检测以细化风险分层,辅助个体化治疗决策。
局限性
- 回顾性设计且样本量为63例,结果需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the utility of genomic testing in risk-stratifying Black patients with low and intermediate risk prostate cancer. METHODS: We retrospectively identified 63 Black men deemed eligible for active surveillance based on National Comprehensive Cancer Network (NCCN) guidelines, who underwent OncotypeDx Genomic Prostate Score testing between April 2016 and July 2020. Nonparametric statistical testing was used to compare relevant features between patients reclassified to a higher NCCN risk after genomic testing and those who were not reclassified. RESULTS: The median age was 66 years and median pre-biopsy PSA was 7.3. Initial risk classifications were: very low risk: 7 (11.1%), low risk: 24(38.1%), favorable intermediate risk: 31(49.2%), and unfavorable intermediate risk: 1 (1.6%). Overall, NCCN risk classifications after Genomic Prostate Score testing were significantly higher than initial classifications (P=.003, Wilcoxon signed-rank). Among patients with discordant risk designations, 28(28/40, 70%) were reclassified to a higher NCCN risk after genomic testing. A pre-biopsy prostate specific antigen of greater than 10 did not have significantly higher odds of HBR (OR:2.16 [95% CI: 0.64,7.59, P=.2). Of favorable intermediate risk patients, 20(64.5%) were reclassified to a higher NCCN risk. Ultimately, 18 patients underwent definitive treatment. CONCLUSIONS: Incorporation of genomic testing in risk stratifying Black men with low and intermediate-risk prostate cancer resulted in overall higher NCCN risk classifications. Our findings suggest a role for increased utilization of genomic testing in refining risk-stratification within this patient population. These tests may better inform treatment decisions on an individualized basis.
引用
- Seiden B, Weng S, Sun N, et al. NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing. Urology. 2021. PMID: 34688772. doi:10.1016/j.urology.2021.08.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。